Trial Profile
A Phase 1b/2, Multicenter, Open-Label, Dose-Escalation and Confirmation Study of Eribulin in Combination With Capecitabine
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer; Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Co Ltd
- 20 Feb 2019 Results published in the British Journal of Cancer
- 10 Aug 2016 Status changed from active, no longer recruiting to completed.
- 06 May 2016 Planned number of patients changed from 116 to 76.